Literature DB >> 2019996

L-2-oxothiazolidine-4-carboxylic acid, a cysteine prodrug: pharmacokinetics and effects on thiols in plasma and lymphocytes in human.

P Porta1, S Aebi, K Summer, B H Lauterburg.   

Abstract

L-2-oxothiazolidine-4-carboxylic acid (OTC), a prodrug of cysteine, was administered at a dose of 0.15 and 0.45 mmol/kg to healthy volunteers. The plasma concentration of OTC reached a peak between 45 and 60 min after p.o. administration. The p.o. clearance of 0.15 mmol/kg of OTC was 0.57 +/- 0.20 liters/(hr.kg) S.D.. The peak increase in plasma OTC was followed by an increase in the plasma concentration of cysteine which rose by 18 to 75 microM over the average basal concentration of 17 microM. The plasma concentrations of free glutathione and total glutathione (i.e., glutathione in small molecular and protein mixed disulfides) did not change significantly during 8 hr after the ingestion of OTC. In contrast, there was a significant increase in the average concentration of cysteine from 0.37 to 0.99 nmol/mg of protein and of glutathione from 8.7 to 15.6 nmol/mg of protein in lymphocytes 2 to 3 hr after ingestion of OTC. The present data shows that OTC is a prodrug of cysteine after p.o. administration in humans and that OTC can raise the circulating concentration of cysteine and the intracellular concentration of cysteine and glutathione in lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2019996

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

1.  Increase in tissue cysteine level and excretion of sulfate and taurine after intragastric administration ofL-2-oxothiazolidine-4-carboxylate in rats.

Authors:  S Yamada; T Abe; J Ohta; N Masuoka; T Ubuka
Journal:  Amino Acids       Date:  1995-03       Impact factor: 3.520

2.  L-2-oxothiazolidine-4-carboxylic acid inhibits human immunodeficiency virus type 1 replication in mononuclear phagocytes and lymphocytes.

Authors:  W Z Ho; S E Starr; A Sison; S D Douglas
Journal:  Clin Diagn Lab Immunol       Date:  1997-05

3.  Effect of procysteine on aging-associated changes in hepatic GSH and SMase: evidence for transcriptional regulation of smpd3.

Authors:  Gergana Deevska; Manjula Sunkara; Claudia Karakashian; Benjamin Peppers; Andrew J Morris; Mariana N Nikolova-Karakashian
Journal:  J Lipid Res       Date:  2014-07-21       Impact factor: 5.922

4.  Transport via SLC5A8 (SMCT1) is obligatory for 2-oxothiazolidine-4-carboxylate to enhance glutathione production in retinal pigment epithelial cells.

Authors:  Ellappan Babu; Sudha Ananth; Rajalakshmi Veeranan-Karmegam; Veena Coothankandaswamy; Sylvia B Smith; Thomas Boettger; Vadivel Ganapathy; Pamela M Martin
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-29       Impact factor: 4.799

5.  L-2-oxothiazolidine-4-carboxylate influence on age- and heat exposure-dependent redox changes in rat's blood plasma.

Authors:  Nikola Hadzi-Petrushev; Nikola Jankulovski; Kiril Hristov; Mitko Mladenov
Journal:  J Physiol Sci       Date:  2011-07-24       Impact factor: 2.781

6.  L-2-Oxothiazolidine-4-carboxylic acid reverses endothelial dysfunction in patients with coronary artery disease.

Authors:  J A Vita; B Frei; M Holbrook; N Gokce; C Leaf; J F Keaney
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

7.  Localization and thiol dependancy of endogenous nitro compounds-mediating urethral photo-relaxation.

Authors:  D Triguero; M González-Herreros; G Costa; A García-Pascual
Journal:  Pflugers Arch       Date:  2007-09-15       Impact factor: 3.657

8.  The systemic availability of oral glutathione.

Authors:  A Witschi; S Reddy; B Stofer; B H Lauterburg
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

9.  Effect ofN-acetylcysteine administration on cysteine and glutathione contents in liver and kidney and in perfused liver of intact and diethyl maleate-treated rats.

Authors:  W B Yao; Y Q Zhao; T Abe; J Ohta; T Ubuka
Journal:  Amino Acids       Date:  1994-10       Impact factor: 3.520

10.  Sulfur-containing therapeutics in the treatment of Alzheimer's disease.

Authors:  Haizhou Zhu; Venkateshwara Dronamraju; Wei Xie; Swati S More
Journal:  Med Chem Res       Date:  2021-01-15       Impact factor: 1.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.